Clarity Pharmaceuticals (ASX:CU6) reported Friday fiscal first-half loss of AU$0.153 per share, compared with a loss of AU$0.074 a year earlier.
Analysts polled by FactSet expected loss of AU$0.08.
Income for the six months ended Dec. 31, 2025, was AU$10 million, compared with AU$10.9 million a year earlier.
The company did not generate revenue from external customers for the period since it is in the development stage and has no commercial products.
Shares of the company rose 13% in recent Friday trade.